Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 42, Issue 4, 2013, Pages 253-259

  Hishitani, Y ^a   Ogata, A ^a   Shima, Y ^a   Hirano, T ^a   Ebina, K ^a   Kunugiza, Y ^a   Shi, K ^a   Narazaki, M ^a   Hagihara, K ^a   Tomita, T ^a   Yoshikawa, H ^a   Tanaka, T ^a   Kumanogoh, A ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CREATINE KINASE; ETANERCEPT; INFLIXIMAB; TOCILIZUMAB;

ADULT; AGED; APPENDICITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DAS28; DISEASE DURATION; DRUG RETENTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERSENSITIVITY; INFECTION; INTERSTITIAL PNEUMONIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RASH; REGISTER; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SUICIDE; TREATMENT DURATION; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84880228981     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.762037     Document Type: Article

References (28)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
2. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012;71:2-45.
3. Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: A systematic quantitative review of randomized controlled trials. Scand J Rheumatol 2011;40:1-7.
4. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644-52.
5. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32.
6. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study. Rheumatology (Oxford) 2011;50:1908-15.
7. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70:1216-22.
8. Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, et al. An observational study of tocilizumab and TNFalpha inhibitor use in a Japanese community hospital: Different remission rates, similar drug survival and safety. Rheumatology (Oxford) 2011;50:2093-9.
9. Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;71:1820-6.
10. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46.
11. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
12. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
13. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, et al. Longterm retention of tumor necrosis factor-a inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA Registry: An appraisal of predictors. J Rheumatol 2012;39:1179-84.
14. Tanaka T, Kishimoto T. Immunotherapeutic implication of IL-6 blockade. Immunotherapy 2012;4:87-105.
15. Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: A large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4.
16. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
17. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. (Pubitemid 47309731)
18. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68:1580-4.
19. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9. (Pubitemid 38725087)
20. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
21. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
22. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broell J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-81.
25. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009;19:351-7.
26. Koike R, Takeuchi T, Eguchi K, Miyasaka N; Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007;17:451-8.
27. Prevoo ML, vant Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel P. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
28. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Prev Med 2007; 45:247-51. (Pubitemid 47562537)